[go: up one dir, main page]

ME03636B - Oksa-diazaspiro jedinjenja која imaju aktivnost protiv bola - Google Patents

Oksa-diazaspiro jedinjenja која imaju aktivnost protiv bola

Info

Publication number
ME03636B
ME03636B MEP-2020-39A MEP202039A ME03636B ME 03636 B ME03636 B ME 03636B ME P202039 A MEP202039 A ME P202039A ME 03636 B ME03636 B ME 03636B
Authority
ME
Montenegro
Prior art keywords
oxa
pain activity
diazaspiro compounds
diazaspiro
compounds
Prior art date
Application number
MEP-2020-39A
Other languages
German (de)
English (en)
French (fr)
Inventor
Marina Virgili-Bernado
Carmen Almansa-Rosales
Carlos Alegret-Molina
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of ME03636B publication Critical patent/ME03636B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-2020-39A 2015-10-23 2016-10-21 Oksa-diazaspiro jedinjenja која imaju aktivnost protiv bola ME03636B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382523 2015-10-23
PCT/EP2016/001742 WO2017067664A1 (en) 2015-10-23 2016-10-21 Oxa-diazaspiro compounds having activity against pain
EP16784795.3A EP3365346B1 (en) 2015-10-23 2016-10-21 Oxa-diazaspiro compounds having activity against pain

Publications (1)

Publication Number Publication Date
ME03636B true ME03636B (me) 2020-07-20

Family

ID=54364221

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2020-39A ME03636B (me) 2015-10-23 2016-10-21 Oksa-diazaspiro jedinjenja која imaju aktivnost protiv bola

Country Status (31)

Country Link
US (1) US10689398B2 (me)
EP (1) EP3365346B1 (me)
JP (1) JP6884973B2 (me)
KR (1) KR20180073638A (me)
CN (1) CN108349998B (me)
AR (1) AR106448A1 (me)
AU (1) AU2016343551A1 (me)
BR (1) BR112018007269A2 (me)
CA (1) CA2999925A1 (me)
CO (1) CO2018004803A2 (me)
CY (1) CY1122708T1 (me)
DK (1) DK3365346T3 (me)
ES (1) ES2775522T3 (me)
HR (1) HRP20200309T1 (me)
HU (1) HUE047997T2 (me)
IL (1) IL258370A (me)
LT (1) LT3365346T (me)
MA (1) MA43158B1 (me)
ME (1) ME03636B (me)
MX (1) MX2018004777A (me)
PH (1) PH12018500682A1 (me)
PL (1) PL3365346T3 (me)
PT (1) PT3365346T (me)
RS (1) RS59956B1 (me)
RU (1) RU2018118399A (me)
SG (1) SG11201802988XA (me)
SI (1) SI3365346T1 (me)
SM (1) SMT202000128T1 (me)
TN (1) TN2018000091A1 (me)
TW (1) TW201731853A (me)
WO (1) WO2017067664A1 (me)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
EP3365346B1 (en) 2015-10-23 2019-12-04 Esteve Pharmaceuticals, S.A. Oxa-diazaspiro compounds having activity against pain

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481942A (en) 1968-09-06 1969-12-02 Smithkline Corp Oxa-diazaspiro(4.5)decane compounds
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
WO1993013101A1 (fr) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
NZ533567A (en) 2001-12-28 2007-06-29 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
KR101167573B1 (ko) * 2003-11-07 2012-07-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
WO2007124136A1 (en) 2006-04-19 2007-11-01 Acadia Pharmaceuticals, Inc. Use of 4-amino-piperidines for treating sleep disorders
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
WO2008105497A1 (ja) 2007-03-01 2008-09-04 Mitsubishi Tanabe Pharma Corporation ベンゾイミダゾール化合物およびその医薬用途
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
US20110190280A1 (en) 2007-08-29 2011-08-04 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
AU2009211251B2 (en) 2008-02-06 2012-02-02 Astrazeneca Ab Compounds
CN102668581A (zh) 2009-10-25 2012-09-12 Lg电子株式会社 用于处理广播节目信息的方法及广播接收器
AU2012229187B2 (en) * 2011-03-14 2016-11-10 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2012125813A1 (en) 2011-03-16 2012-09-20 Access Business Group International Llc Humidifier with ultraviolet disinfection
EP2744333B1 (en) 2011-08-19 2016-10-05 Glaxosmithkline Intellectual Property (No. 2) Limited Fatty acid synthase inhibitors
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP2017100951A (ja) 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
TWI685497B (zh) 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
WO2016078771A1 (en) 2014-11-21 2016-05-26 Laboratorios Del Dr. Esteve, S.A. 1,9-diazaspiro undecane compounds having multimodal activity against pain
EP3365346B1 (en) 2015-10-23 2019-12-04 Esteve Pharmaceuticals, S.A. Oxa-diazaspiro compounds having activity against pain

Also Published As

Publication number Publication date
RS59956B1 (sr) 2020-03-31
TW201731853A (zh) 2017-09-16
ES2775522T3 (es) 2020-07-27
KR20180073638A (ko) 2018-07-02
SG11201802988XA (en) 2018-05-30
US20190002475A1 (en) 2019-01-03
LT3365346T (lt) 2020-04-10
CY1122708T1 (el) 2021-03-12
TN2018000091A1 (en) 2019-07-08
US10689398B2 (en) 2020-06-23
SI3365346T1 (sl) 2020-04-30
CN108349998B (zh) 2021-10-29
HRP20200309T1 (hr) 2020-06-12
PL3365346T3 (pl) 2020-06-01
SMT202000128T1 (it) 2020-05-08
PT3365346T (pt) 2020-03-05
WO2017067664A9 (en) 2017-06-29
EP3365346B1 (en) 2019-12-04
DK3365346T3 (da) 2020-03-09
RU2018118399A (ru) 2019-11-25
MX2018004777A (es) 2018-06-19
WO2017067664A1 (en) 2017-04-27
EP3365346A1 (en) 2018-08-29
AR106448A1 (es) 2018-01-17
JP2018531263A (ja) 2018-10-25
RU2018118399A3 (me) 2020-01-31
AU2016343551A1 (en) 2018-04-19
CA2999925A1 (en) 2017-04-27
JP6884973B2 (ja) 2021-06-09
CN108349998A (zh) 2018-07-31
MA43158B1 (fr) 2020-03-31
IL258370A (en) 2018-05-31
BR112018007269A2 (pt) 2018-10-30
CO2018004803A2 (es) 2018-07-19
PH12018500682A1 (en) 2018-10-01
HUE047997T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
MA40551A (fr) Composés actifs envers des bromodomaines
HRP20190165T1 (hr) Genska terapija za fabryjevu bolest
ZA201704557B (en) Use of picolinamide compounds with fungicidal activity
ZA201704559B (en) Use of picolinamide compounds with fungicidal activity
PL3240773T3 (pl) Związki pikolinamidowe o aktywności grzybobójczej
EP3360864A4 (en) pyrimidine
MA44050A (fr) Nouveaux composés
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
DK3262066T4 (da) Genterapi
EP3445750A4 (en) THERAPEUTIC COMPOUNDS
MA53755A (fr) Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité comme agonist de taar
DK3167052T3 (da) P450-bm3-varianter med forbedret aktivitet
EP3728289A4 (en) OPTIMIZED CONNECTIONS
EP3372588A4 (en) pyrimidine
LT3191514T (lt) Ligandai, sustiprinantys gonadotropinų biologinį aktyvumą
HUE056544T2 (hu) Gamma-C-citokin aktivitás modulálása
EP3310352A4 (en) CRYSTALLINE COMPOUNDS
EP3270766C0 (en) Eeg monitor
EP3259254A4 (en) THERAPEUTIC COMPOUNDS
DK3329004T3 (da) Terapeutiske oligonukleotider
PT3170887T (pt) Fermentador melhorado
IL257971A (en) Materials with combined activity
ME03636B (me) Oksa-diazaspiro jedinjenja која imaju aktivnost protiv bola
DK3317493T3 (da) Ekspanderbar, bor-bar sko
EP3325497A4 (en) QUINSTATINVERBINDUNGEN